The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.
A federal appeals panel on Friday halted the reinstatement of two independent agency members fired by President Trump, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback